.jpg)
LUMICKS is proud to be recognized as an Innovation Champion at the TechEU Equity Summit 2026. (Photo: Vio Dudau/EIB)
We are deeply grateful to the European Investment Bank (EIB) for this recognition and for its continued partnership in supporting innovation that has the potential to transform cancer drug discovery. Through its venture debt financing, the EIB has played an important role in helping LUMICKS accelerate the development and commercialization of innovative technologies for researchers worldwide.
This recognition reflects the collective effort of an incredible team of scientists, engineers, product developers, commercial teams, customers, investors, and partners who share a common goal: accelerating the discovery of better therapies.
One of the most significant milestones on this journey has been the launch of Avidion, LUMICKS' high-throughput cell avidity platform. Avidion enables researchers to directly measure interactions between immune cells and cancer cells, providing insights that can help improve decision-making in the development of next-generation immunotherapies.
At LUMICKS, our mission remains clear: to empower researchers with technologies that reveal deeper biological insights and help accelerate the development of life-saving therapies.
We share this recognition with our employees, customers, partners, investors, and the broader European innovation ecosystem who continue to support this mission.
Together, we are helping shape a future where promising immunotherapies reach patients faster.
